Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, tolerable, and targeted th...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Med
Main Authors: Darici, Salihanur, Alkhaldi, Hazem, Horne, Gillian, Jørgensen, Heather G., Marmiroli, Sandra, Huang, Xu
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563273/
https://ncbi.nlm.nih.gov/pubmed/32932888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092934
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items